High-power lineup to headline retailer-supplier summit
NEW YORK Drug Store News Issues Summit and Diabetes Roundtable. —“This is simply the best, most diverse lineup of retailers we have ever had.” That’s the way John Kenlon, SVP Lebhar-Friedman Retail Group, described the panelists confirmed for the 12th Annual
And that could be an understatement. The DSN Issues Summit brings together a highly diverse group of retailers and key supplier executives in a series of top-to-top panel discussions moderated by DSN. Confirmed panelists include top executives from such retailers as H-E-B, Costco, Fred Meyer, Rite Aid, Wegmans, Ulta Beauty, Walgreens, Sam’s Club, McKesson’s HealthMart, Ace Hardware, exciting new healthcare retailer Max-Wellness, Giant Eagle, Kerr Drug and many more.
For retailers, the annual one-day, must-attend conference—slated for Tuesday, Nov. 30 at Manhattan’s historic New York Athletic Club—is an ideal opportunity to reconnect with important business partners; for suppliers, it is an important chance to network with leading retail executives who influence critical buying decisions every day.
In addition to the Issues Summit portion of the program, which is premised upon better aligning retailer and supplier objectives with the end goal of growing the business unilaterally, DSN also will convene its Eighth Annual Diabetes Roundtable, which is targeted on the opportunities to better serve the needs of patients living with the disease.
“This one-day event provides unprecedented access to a multiple list of leading-edge retailers from many formats,” said Wayne Bennett, publisher of The Drug Store News Group. The event, which is timed to coincide with the annual NACDS Week, ties in “nicely with several key committee meetings, including the NACDS Foundation dinner later that evening,” Bennett added.
As a special addition to the program, DSN will open its Specialty Pharmacy Leadership Roundtabel to attendees. Specialty pharmacy providers CVS Caremark and Walgreens Specialty Pharmacy are among confirmed panelists. The icing on the cake for attendees: CNBC star/national radio host/syndicated columnist Larry Kudlow will deliver the keynote presentation, “Never Sell America Short: Free-Market Capitalism and the American Economy” at the exclusive event.
Current sponsor companies include Pacific World, Kao Brands, Novartis Consumer Health, Takeda, Pharmavite, TABS, Catalina Marketing, Alberto-Culver, Nipro Diagnostics and GlaxoSmithKline Consumer Healthcare.
‘Picture This’ forums bring diabetes management awareness to public
PRINCETON, N.J. A few days after it released a report on how awareness and education play an integral role in the prevention, detection and treatment of diabetes, Novo Nordisk is bringing it to the public.
The drug maker said Friday that, through its collaboration with the Entertainment Industries Council, it will host "Picture This" forums, which include an open discussion among diabetes stakeholders and the media to identify top diabetes communication challenges, explore strategies to address those priorities and strengthen community understanding about diabetes through news media and community affairs programs.
The forums will be held in Philadelphia on Oct. 22 and Seattle on Nov. 18.
"Novo Nordisk is proud to join EIC, the media and community leaders in Seattle and Philadelphia to explore ways to improve how diabetes is communicated about and understood by local citizens," said Tony Deluzio, senior medical director at Novo Nordisk. "As the prevalence of diabetes continues to be on the rise, bringing together those on the front line of diabetes care will open the potential to reduce the stigma associated with diabetes and empower those affected by the disease to lead full and productive lives."
Pfizer makes official tender offer for King
NEW YORK Pfizer officially has made its tender offer to buy King Pharmaceuticals for $3.6 billion, or $14.25 per share, Pfizer said Friday.
The offer constitutes a 40% premium over the closing price of King’s stock on Oct. 11, when Pfizer originally made the offer. King, based in Bristol, Tenn., specializes in pain medications designed to deter misuse and abuse, and Pfizer said the acquisition would enhance its position in the pain-relief market.
The offer expires at midnight on Nov. 19.